De novo malignancy development following kidney transplantation: Managing risks and outcomes in clinical practice
Year: 2025
Type: article
Study design: Observational Study
Abstract: In this study, we aim to assess the frequency, risk factors, and medical results of de novo malignancy after kidney transplant surgery, thereby shedding light on potential strategies to improve both recipient and transplant viability.By elucidating the challenges faced in clinical practice, our findings may contribute to the development of individualized management approaches that enhance patient prognosis and reduce the burden of cancer in kidney transplant recipients. MATERIAL and METHODSThis a retrospective cohort analysis was performed at a single tertiary care facility from January 2016 and December 2023.An overall count of 1200 individuals who underwent kidney transplantation within the stated timeframe were incorporated ABSTRACT Objective: De novo malignancy is a significant complication following kidney transplantation, attributed to prolonged immunosuppression.This study evaluates the incidence, risk factors, and clinical outcomes of de novo malignancies in kidney transplant recipients. Material and Methods:A retrospective cohort analysis was conducted on 1200 kidney transplant recipients between 2016 and 2023.Patients were categorized based on the presence or absence of de novo malignancies.Statistical analyses were performed to identify risk factors, including age, sex, comorbidities, and immunosuppressive regimens.Patient and graft survival were assessed using Kaplan-Meier analysis and the log-rank test.Results: Among the study population, 43 patients (3.6%) developed de novo malignancies.The most frequent malignancy types were non-melanoma skin cancers (27.9%) and post-transplant lymphoproliferative disorders (18.6%).Patients with malignancies exhibited a lower three-year survival rate (83.7%) compared to those without malignancies (91.4%), though the difference was not statistically significant (p=0.067).Graft survival at three years was slightly lower in the malignancy group (84.0% vs. 88.7%,p=0.146).Older recipient age was identified as a significant risk factor (hazard ratio=1.03 per year, p=0.025).Conclusion: De novo malignancy remains a concern in kidney transplant recipients, particularly among older patients.Regular screening protocols, lifestyle interventions, and individualized immunosuppressive regimens are essential to mitigate risk and improve outcomes.
Source: Turkish Journal of Surgery
Authors: Amil Huseynov, Sevim Nuran Kuşlu Çiçek
Institutions: Beykoz Üniversitesi, Biruni University
Language: English
Subfield: Transplantation
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4417104044
FWCI:
Cites:
Cited by:
Related to: